BioInvent International’s Annual Report 2020 published
Lund, Sweden, April 8, 2021 – BioInvent International AB (publ) (Nasdaq Stockholm: BINV) today announced that the Annual Report for 2020 is published and available at the company’s website, www.bioinvent.com. About BioInventBioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s